TheStreet's co-portfolio manager Jim Cramer says DexCom is a poster child for what is both right and wrong with today's market. DexCom, which makes a device to monitor glucose remotely with no finger pricking, is a disruptive technology that is taking the Type One diabetes world by storm. Cramer says the stock has taken a hit when investors stopped paying attention to cash flow positive stocks and started focusing on earnings per share instead. DexCom has added expenses because they are hiring more salespeople, but Cramer expects the device maker to be cash flow positive in 2015. Cramer believes the stock will turnaround next year.

More from Video

2 Things Fed Chairman Jerome Powell Just Said Upset Investors

2 Things Fed Chairman Jerome Powell Just Said Upset Investors

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer on Starbucks: There Are Multiple Problems Here

Jim Cramer on Starbucks: There Are Multiple Problems Here

Jim Cramer on the Problem With the Case for More Rate Hikes

Jim Cramer on the Problem With the Case for More Rate Hikes

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries